Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Cure Genetics to Develop AAV Vectors for Neuro Startup in $60 Million Deal

publication date: Sep 15, 2023

Suzhou Cure Genetics, a cell and gene therapy company, announced a $60 million deal to create AAV vectors for Hong Kong’s Frametact, a neurodegenerative disease startup. Frametact was founded by a molecular neuroscience research team at The Hong Kong University of Science and Technology and Hong Kong Center For Neurodegenerative Diseases. It targets familial diseases that include Alzheimer's, Parkinson's and Huntington's disease. Cure, which will apply its VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors, will receive $60 million in upfront and milestone payments, plus royalties on revenues. More details...

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital